Much, much more to come.22 Dec 2021 08:33
Happy days. Key points to note are that any risk of running out of cash in the forseeable future has been banished, and for the eagle eyed no 'ifs or buts' in the tail end text of the RNS regarding AVA6000, "targeted chemotherapy platform which releases active chemo in the tumour, which limits the systemic exposure that causes damage to healthy tissue ...". Much, much more good news to come. Nice little present for Christmas, thanks AL.